IκBα Nuclear Export Enables 4-1BB–Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity

Tags

  • Category: Articles

AUTHORS 

Dominique N. Lisiero, Zhang Cheng, Melba M. Tejera, Brandon T. Neldner, Jay W. Warrick, Shelly M. Wuerzberger-Davis, Alexander Hoffmann, M. Suresh and Shigeki Miyamoto

SUMMARY

Optimal CD8 T cell immunity is orchestrated by signaling events initiated by TCR recognition of peptide Ag in concert with signals from molecules such as CD28 and 4-1BB. The molecular mechanisms underlying the temporal and spatial signaling dynamics in CD8 T cells remain incompletely understood. In this study, we show that stimulation of naive CD8 T cells with agonistic CD3 and CD28 Abs, mimicking TCR and costimulatory signals, coordinately induces 4-1BB and cRel to enable elevated cytosolic cRel:IκBα complex formation and subsequent 4-1BB-induced IκBα degradation, sustained cRel activation, heightened IL-2 production and T cell expansion. NfkbiaNES/NES CD8 T cells harboring a mutated IκBα nuclear export sequence abnormally accumulate inactive cRel:IκBα complexes in the nucleus following stimulation with agonistic anti-CD3 and anti-CD28 Abs, rendering them resistant to 4-1BB induced signaling and a disrupted chain of events necessary for efficient T cell expansion. Consequently, CD8 T cells in NfkbiaNES/NES mice poorly expand during viral infection, and this can be overcome by exogenous IL-2 administration. Consistent with cell-based data, adoptive transfer experiments demonstrated that the antiviral CD8 T cell defect in NfkbiaNES/NES mice was cell intrinsic. Thus, these results reveal that IκBα, via its unique nuclear export function, enables, rather than inhibits 4-1BB-induced cRel activation and IL-2 production to facilitate optimal CD8 T cell immunity.

REFERENCES

Dominique N. L., Zhang C., Melba M. T. et al. IκBα Nuclear Export Enables 4-1BB-Induced cRel Activation and IL-2 Production to Promote CD8 T Cell Immunity. J Immunol September 15, 2020, 205 (6) 1540-1553; DOI: https://doi.org/10.4049/jimmunol.2000039

PRODUCT HIGHLIGHTS

The following Bio X Cell in vivo monoclonal antibodies were featured in the publication: 

Back to News

Meet Our Leaders

Learn more about the team behind the gold standard in vivo antibodies.

Discover Bio X Cell

Learn more about our proven expertise and comprehensive antibody solutions.

See Our Impact

Discover the Bio X Cell Fund’s mission to improve the health of our community

Explore Our Latest

See our latest articles and whitepapers for scientific insights and ideas

Don’t see what you need?

Consult With Bio X Cell to Enable Your Next Breakthrough Discovery

Whether you need antibody customization or high-volume production, Bio X Cell is committed to advancing your therapeutic innovations.

Contact Us